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ABSTRACT
The diagnosis and treatment of neurosarcoidosis can be very challenging for several reasons.
It affects clinically 5%–10% of sarcoidosis patients, but can be found in up to 25% of autopsies.
These data reveal that a high percentage of asymptomatic or misdiagnosed cases can be missed at
an initial diagnostic approach. Clinical and imaging findings are often non-specific since they can
be found in a large number of neurological disorders. Histopathology can also be confounding if
not performed by an expert pathologist and not placed in an appropriate clinical context. In this
review, we discuss clinical features, laboratory findings, imaging, and histology of neurosarcoidosis,
and we report current evidence regarding drug therapy. We conclude that a correct diagnostic
approach should include a multidisciplinary evaluation involving clinicians, radiologists, and
pathologists and that future studies should evaluate the genetic signature of neurosarcoidosis
as they could be helpful in the assessment of this uncommon disease. With head-to-head
comparisons of medical treatment for neurosarcoidosis still lacking due to the rarity of the disease
and an increasing number of immunomodulating therapies at hand, novel therapeutic approaches
are to be expected within the next few years.
KEY MESSAGES
 Neurosarcoidosis is a rare disorder that affects clinically 5%–10% of sarcoidosis patients, but can
be found in up to 25% of autopsies, revealing that a high percentage of asymptomatic or
misdiagnosed cases can be missed at an initial diagnostic approach.
 A multidisciplinary evaluation is useful to achieve a correct diagnosis because clinical and
imaging findings are often non-specific.
 Corticosteroids are the first-line treatment for neurosarcoidosis, followed by steroid-sparing
immune-modulating agents if prednisone therapy is insufficient.
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Introduction
Sarcoidosis is a chronic idiopathic, inflammatory disorder
characterized by multi-organ involvement by non-case-
ating granulomas. The epidemiology in general is quite
complex as it shows variability due to a different racial
and geographical distribution. In general, it occurs most
often in countries of Northern Europe and United States
and affects most frequently females.
The annual incidence is highest among African-
Americans (39.1 and 29.8 cases/100,000 in females
and males, respectively) followed by Caucasians (12.1
and 9.6/100,000), and peaks in patients aged 20–49
years, a decade sooner in African-Americans than in
Caucasians (30–39 versus 40–49, respectively) (1–3).
African-Americans are also at an increased risk of
mortality, tendency to multi-organ involvement, and
disease chronicity (3). Lungs and intrathoracic lymph
nodes are the sites most frequently involved (2,4,5), but
virtually no tissue or organ is spared from sarcoidosis as
it can involve organs such as heart, skin, gastrointestinal
tract, liver, spleen, and joints. The involvement of central
and peripheral nervous system (neurosarcoidosis) is
uncommon, and the diagnosis can be very challenging
if not clinically suspected, resulting in highly significant
morbidity and mortality. Neurosarcoidosis manifests
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clinically in 5%–10% of patients with sarcoidosis, but can
be identified in up to 25% of autopsies. Clinical
presentation can be isolated or, more commonly,
associated with other symptoms of systemic involve-
ment such as pulmonary or eye disease (6). Like the
systemic form, it affects black more frequently
than white people, and the disease is more common
in females (7). However, neurosarcoidosis seems to occur
slightly later than the systemic form of the disease
(mean age of onset between 33 and 41 years) (8,9).
Children are rarely affected with neurosarcoidosis, most
commonly at the age of 9–15 years (10). The discordance
between incidence of clinical and autopsy studies in
adults reveals a great number of asymptomatic, under-
or misdiagnosed cases, highlighting the need for robust
criteria to recognize the disease early. In this narrative
review we focus on clinical, radiological, and histopatho-
logical features of neurosarcoidosis, reviewing current
diagnostic algorithms that can help toward early iden-
tification of this uncommon disorder. Current evidence
on therapy and future perspectives will be also
discussed.
Etiology of sarcoidosis and selective
involvement of the nervous system
It is currently debated why some patients with sarcoid-
osis present mostly neurological rather than pulmonary
manifestations of the disease. The formation of non-
caseating granulomas in general seems to represent the
result of an incomplete degradation of foreign or self-
antigenic stimuli in genetically predisposed individuals,
associated with an excessive activity of macrophages
and T- and B-cells due to prolonged antigenemia
(11–13). Several environmental factors have been dis-
cussed as trigger agents, the most commonly accepted
being those deriving from infectious disorders (e.g.
mycobacteria and viruses), neoplasms, inorganic com-
pounds (e.g. aluminium), or those derived from occupa-
tional exposure (e.g. agricultural employment or
insecticides used at work) (14–17).
The environmental factors, however, could not justify
the onset of the disease alone, but can influence the
development of sarcoidosis in genetically predisposed
subjects. Genetic mutations, such as those involving the
genes encoding for annexin A11 protein and butyrophi-
lin-like 2 (BTNL2) (18,19), seem to influence the disease
susceptibility and clinical progression (20,21). Some of
them have been linked to certain clinical phenotypes,
suggesting a predisposition to manifest a specific organ
involvement (e.g. HLA-DRB1*0301 mutation and TGF-b 3
polymorphism as independent genetic risk factors for
Lo¨fgren’s syndrome and pulmonary fibrosis, respect-
ively) (22–25).
In this regard, there is increasing evidence of a specific
genetic predisposition to a selective sarcoid involvement
of the nervous system in some patients (26–28).
Caucasians present more often with manifestations
deriving from peripheral nervous system involvement
than do African-Americans, and patients with small fiber
neuropathy have a high frequency of HLA-DQB1*0602
antigen and non-HLA polymorphic gene occurrence (26).
A genetically predisposed condition of selective
involvement of the nervous system can also be sug-
gested by the evidence of a significant and specific
elevation of some biomarkers in neurosarcoidosis in
comparison to controls, revealing that neurosarcoidosis
could be sustained partly by specific genetic profiles as
found for sarcoidosis in general (29–31).
Clinical manifestations of neurosarcoidosis
Neurologic involvement of sarcoidosis encompasses a
variety of clinical manifestations affecting both central
and peripheral nervous system. Myopathy is also
described among presentation conditions of neurosar-
coidosis, although it occurs rarely. The frequency of the
clinical manifestations is discordant in the different case
series, perhaps reflecting the non-specific or paucisymp-
tomatic presentation in most cases (9).
Central nervous system (CNS) sarcoidosis
The CNS involvement can be divided into two cate-
gories: brain and spinal cord neurosarcoidosis (BNS and
SNS, respectively). BNS can present with non-specific
symptoms such as fatigue, headache, cognitive dysfunc-
tion with progressive decline, fever, nausea, vomiting,
and mood disorders (8,26,32–34).
Fatigue is a core symptom of neurosarcoidosis and
seems to influence the cognitive functions in the
affected patients, but is not specific as it can be found
in several conditions such as sleep disorders, hypothy-
roidism, hypogonadism, hyponatremia, hypocortisolism,
and (steroid) myopathy. Clinical and laboratory findings
can orient toward a specific endocrine and/or metabolic
disease rather than CNS sarcoidosis. Furthermore,
fatigue can also occur in association with peripheral
nervous system disease (35). The clinical picture of CNS
sarcoidosis is most often dominated by cranial neur-
opathy secondary to granulomatous infiltration or to
basilar, aseptic meningitis (9), being described in up to
80% of cases (8). In particular, most studies show that
the optic nerve (II) is the most frequently affected,
followed by the facial (VII) nerve. It is unknown whether
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these results reflect a greater likelihood of referral of
patients with CN II dysfunction to centers of excellence
as compared to facial neuropathy patients, who are
more often managed in a community setting (6,8,36).
The damage of the II nerve from neurosarcoidosis can be
associated with a poor prognosis in terms of visual
recovery (8). Main findings are central loss or blurred
vision, retrobulbar pain, optic nerve atrophy, and
papilledema resulting from local granuloma formation
(8,37,38). The VII nerve paresis is usually evident unilat-
erally and less frequently affects both sides of the face
(26,35,39). Rarely, the involvement of the VII nerve is
associated with other specific symptoms such as
Heerfordt’s syndrome, a clinical variety characterized
by facial nerve palsy, fever, swelling of the parotid
glands, and uveitis (40). Hearing loss and vestibular
dysfunction manifesting with dizziness are usually due
to VIII nerve impairment (6). Descriptions of trigeminal
nerve (V) dysfunction, presenting, most often, with facial
paresthesias and hyperesthesia and, rarely, with typical
neuralgia, and of the nerves involved in eye movements
(III, IV, and VI) have also been reported in the literature
(41–43). Other clinical findings of BNS are seizures or
focal neurological deficits such as hemiparesis, often
associated with brain tumor-like lesions exerting mass
effect (37,38,44,45), and dysfunction of the endocrine
system, which most commonly presents with diabetes
insipidus, gonadotropin and TSH deficiency, and hyper-
prolactinemia (46). Rarely, focal deficits can be secondary
to the occurrence of an ischemic or hemorrhagic stroke,
resulting from infiltration of vessel walls by granulomas
(47–50).
SNS is reported rarely, in about 14% of the cases in a
recent study (51). Unlike BNS, where symptoms occur
within 2 years after diagnosis (9), SNS manifestations are
clinically evident later, and the patients have a higher
age of onset (52). SNS can be classified by location into
intramedullary, extramedullary with leptomeningeal
involvement, extradural, vertebral neurosarcoidosis,
and disease of the disk space. The thoracic region is
often involved (53). Main presenting symptoms are
paresthesias and weakness of the lower extremities (51).
Rarely, cases of sudden paraplegia have been described
(54). Bowel, bladder, erectile, and ejaculatory dysfunc-
tion have also been described as additional symptoms of
spinal cord disease (55).
Sarcoidosis of the peripheral nerves
Sarcoidosis of the peripheral nervous system (PNS) can
affect up to 40% of patients, more often Caucasians than
Afro-Americans. These data seem to be in part related to
a genetic predisposition (26), as discussed above.
Sarcoid-related neuropathy can be mono- or multifocal
associated with conduction blocks or present as poly-
radiculoneuropathy, sometimes in the form of Guillain–
Barre´-like syndrome. More often, however, it presents as
symmetrical sensory motor polyneuropathy (56–60).
In rare cases an atypical chronic inflammatory demye-
linating polyneuropathy has also been described (61).
Small-fiber neuropathy with or without involvement of
autonomic fibers may occur and cause debilitating
symptoms such as pain or restless leg syndrome (62).
The type and severity of symptoms can be assessed
using quantitative sensory testing and related
techniques (63).
However, in cases of suspected neurosarcoidosis
with clinical involvement of the PNS, a nerve biopsy is
essential to confirm the diagnosis (56).
Sarcoidosis-related myopathy
Granulomatous involvement of the muscles is often
asymptomatic and found mostly at autopsy in up to 75%
of all cases (64); only rarely (less than 1%) does it present
with acute, although non-specific, findings such as
muscle atrophy, weakness, and pain (26). In this
regard, a useful classification includes acute, chronic,
and nodular myositis. Acute myositis is characterized by
non-specific symptoms such as fever and fatigue
associated with muscle swelling, disabling pain, and
sometimes contractures. The chronic form affects most
often multiple groups of muscles, while the nodular
involvement presents as multiple tumor-like masses
found on muscle palpation (64).
Laboratory tests
Systemic sarcoidosis is diagnosed based on the clinical
picture and the histological evidence of granulomatous
inflammation from cell or tissue specimens, such as
lymph node biopsy or bronchoalveolar lavage (4,65).
Accordingly, the diagnosis of definite neurosarcoidosis
requires a positive CNS or nerve biopsy. Peripheral
nervous system tissue is more accessible and therefore
appropriate to undergo biopsy in the proper circum-
stances (66). However, due to the broad spectrum of
clinical manifestations and lack of certainty from other
(e.g. imaging) diagnostic modalities, establishing the
diagnosis of neurosarcoidosis is difficult. Biomarkers in
serum and spinal fluid have been extensively studied for
their ability to aid in the diagnosis (67). Potentially, they
could provide evidence of CNS involvement in known
systemic sarcoidosis, or guide toward neurosarcoidosis
in cases where the disease has not manifested system-
ically. Although certain immunological parameters are
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known to be affected in sarcoidosis, none of the
investigated serum biomarkers have been accepted
as establishing the diagnosis including angiotensin-
converting enzyme (ACE) or soluble interleukin-2
receptor activity (sIL2 receptor) in the blood.
The Kveim–SilzenbachQ1 test, which involves intradermal
injection of tissue extracts from human sarcoidosis
patients, has been used by some institutions with a
reasonable specificity (2), but has been abandoned by
many others due to concerns regarding risk of infection
and lack of standardized and commercially available
test agents (68).
In the original Zajicek criteria, the following laboratory
tests are required for the diagnosis of at least probable
neurosarcoidosis: ‘. . . laboratory support for CNS inflam-
mation (elevated levels of CSF protein and/or cells, the
presence of oligoclonal bands and/or MRI evidence
compatible with neurosarcoidosis) and exclusion of
alternative diagnoses together with evidence of systemic
sarcoidosis (either through positive histology, including
Kveim test, and/or at least two indirect indicators from
Gallium scan, chest imaging and serum ACE)’ (37). In
their relatively large series of 68 patients, serum ACE was
only increased in 23.5%, while calcium was normal in all,
and erythrocyte sedimentation rate (ESR) positive in four.
This is in line with observations from other groups:
neither serum ACE nor calcium or ESR is useful to
establish the diagnosis of neurosarcoidosis (69,70).
Cerebrospinal fluid findings indicative of a chronic
inflammatory disease have a much higher diagnostic
yield in neurosarcoidosis (71). An important part of the
initial CSF examination is to rule out infectious CNS
disease and malignancy.
In the work by Zajicek et al., CSF protein was elevated
in 73%, leukocyte count raised in 55%, positive
oligoclonal bands in CSF or both CSF and serum found
in 55% (37). Increased sIL2 receptor activity in the CSF
might actually help to discriminate neurosarcoidosis
from other chronic inflammatory CNS diseases (31). Cells
in the CSF (number and type of cells) as well as antibody
indices (IgM, IgA, IgG) are often pathologic and may
reflect disease activity (72). ACE in spinal fluid, despite a
low sensitivity (24%–55%), might raise the suspicion of
neurosarcoidosis due to its high specificity (94%–95%)
(73). The CD4/CD8 T-cell ratio is typically increased in
bronchoalveolar lavage of sarcoidosis patients (74).
In neurosarcoidosis, the diagnostic utility of this test is
uncertain (75,76).
In summary, laboratory tests are only one component
of the complex diagnostic process leading toward
neurosarcoidosis. While blood biomarkers have a very
limited value, CSF findings are compatible with a chronic
CNS infection in the majority or patients. In a group of
patients with neurosarcoidosis diagnosed at our clinic,
CSF was abnormal in 12 out of 13 (70).
Currently, sIL2-receptor alpha chain levels above
150 pg/mL are most specific for CNS involvement by
sarcoidosis (overall accuracy of 93%) (31).
Electromyography, nerve conduction, and
evoked potential studies
The presence of neuropathy and myopathy can be
revealed by nerve conduction studies (NCS) and elec-
tromyography (EMG). When peripheral nerves are
affected, NCS can reveal anomalous sensory or motor
nerve conduction consisting of absent/small potentials
and reduced velocities, respectively (8). Also quantitative
sensory and autonomic testing can be helpful in the
evaluation of small fiber neuropathy (63).
EMG confirms myopathy by revealing myopathic
motor unit potentials. Both NCS and EMG findings can
improve after appropriate cortisone and/or immunosup-
pressive therapy (8).
Brainstem auditory and visual evoked potentials are
abnormal in up to 35% and 43% of patients, respectively,
while somatosensory evoked potentials are less fre-
quently altered. Evoked potentials can be abnormal
often in asymptomatic cases, revealing a subclinical
nervous system involvement in sarcoidosis, which can
help in the early diagnosis of the disease (77,78).
The role of imaging
Imaging techniques give useful clues in the diagnosis
and staging of systemic sarcoidosis. Chest X-rays and
abdominal ultrasound are useful to reveal and classify
the organ involvement, but procedures such as high-
resolution computed tomography (HRCT), contrast-
enhanced magnetic resonance imaging (CEMRI), and
positron emission tomography with fluorodeoxyglucose
(FDG-PET) have higher sensitivity to document the
degree of the involvement and are preferred in most
cases (79–81). Recently, contrast-enhanced ultrasound
(CEUS) has demonstrated a great potential in the
diagnosis and assessment of the disease, also in the
cases in which non-enhanced ultrasound is traditionally
not significant (82–85).
While the diagnosis of neurosarcoidosis can be easily
suspected in patients with overt systemic disease with
signs of neurological dysfunction, isolated neurosarcoi-
dosis raises great diagnostic difficulty due to non-
specific findings on imaging. However, the contribution
of imaging (e.g. CT and MRI) is essential as it can
demonstrate the central and peripheral nervous system
involvement and also provide useful information to
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guide biopsy or follow-up of patients over time. FDG-PET
can define areas of systemic hypermetabolism that can
facilitate targeted tissue biopsy for diagnosis. An accur-
ate and early recognition of nervous system involvement
can allow a prompt and appropriate treatment, thus
avoiding the onset of severe and/or irreversible compli-
cations that can potentially increase morbidity and
mortality. Imaging findings should not be considered
alone but only in an appropriate diagnostic algorithm
including clinical, laboratory, radiological, and histo-
pathological findings, to avoid misdiagnosis or classifi-
cation of suspected cases (see below).
CT
CT is less sensitive than MRI for many of the imaging
manifestations of CNS sarcoidosis. Granulomatous
involvement can be extra- or intra-axial and can be
classified according to the site affected, namely basilar,
convexity, intrahemispheric, and periventricular white
matter. CT can demonstrate nodular or diffuse lepto-
meningeal thickening after iodine contrast injection or
as singular or multiple hyperdense, enhancing tumor-
like lesions with edema of the adjacent white matter or
mass effect to the adjacent parenchyma (86). CT can
sometimes reveal optic chiasma and nerve enhancement
after iodine contrast administration, and can demon-
strate the presence of hydrocephalus or uncommon
findings such as parotid, salivary, and lacrimal gland
enlargement (87), calcifications, and hemorrhagic stroke
(86). However, CT has very low sensitivity to assess
the typical small areas of ischemic injury caused by
sarcoidosis-associated vasculopathy (86).
MRI
MRI is the preferred diagnostic imaging technique for
evaluation of neurosarcoidosis as it gives the best
definition for brain and spinal disease. Leptomeningeal
involvement manifests as diffuse or nodular thickening
and enhancement on contrast-enhanced T1-weighted
images (Figure 1), with a predilection for the basilar
meninges, a pattern that is often similar to that
observed with tuberculosis or lymphoma (Figure 2).
Intraparenchymal lesions can manifest as multiple small,
non-enhancing periventricular or subcortical white
matter lesions giving high signal on T2-weighted
images, similarly to those observed in multiple sclerosis
(MS) (53). Unlike MS, periventricular lesions in neurosar-
coidosis do not usually resemble Dawson’s fingers.
Larger lesions present as enhancing parenchymal
masses involving leptomeningi and giving edema on
the healthy parenchyma. These nodules can be easily
misdiagnosed as primary or metastatic tumors. MRI also
demonstrates well cranial nerve involvement (Figure 2),
although there is no close relationship between clinical
and imaging findings (patients can be symptomatic with
negative MRI and vice versa). When present, nerve
disease can manifest as uni- or bilateral enlargement
with enhancement of cranial nerves on contrast-
enhanced T1-weighted images. In the case of optic
nerve disease (Figure 1), an infiltrative, pseudotumor-like
lesion involving periorbital tissue can be observed.
Similar enhancement patterns have been reported also
for pituitary gland, hypothalamus, and dural involve-
ment (53). Imaging features of spinal neurosarcoidosis
vary according to the site involved. Intraspinal lesions
appear as hyperintense on T2- and hypointense on T1-
weighted images, with patchy infiltration after gadolin-
ium administration and fusiform enlargement of cervical
and thoracic segments. Extraspinal disease, in particular
leptomeningeal involvement, usually manifests as thin
linear enhancement and small lesions or, rarely, as
sarcoid nodules hypo- and hyperintense on T1- and T2-
weighted images (Figure 3). MRI also shows bone lesions
well, demonstrating similar findings after gadolinium
administration (53,88).
FDG-PET
FDG-PET can be useful to assess metabolic activity of
systemic sarcoidosis and has demonstrated a high
Figure 1. MRI pituitary, coronal T1 post-contrast image:
leptomeningeal enhancement with nodularity involving both
infra- and supratentorial regions, especially prominent around
the suprasellar cistern and the optic chiasm (arrows). Courtesy of
Dr Fang Zhu, Chicago.
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efficacy in assessing stage, disease activity, and occult
sites and in monitoring response to the therapy.
In particular, the sensitivity and diagnostic accuracy of
18-FDG-PET is significantly higher than traditional 67Ga
scintigraphy. FDG-PET can reveal areas of systemic
hypermetabolism corresponding to active lesions and
can be useful to reveal occult and asymptomatic sites to
be examined histologically (89), but there is a lack of
evidence regarding its utility in neurosarcoidosis (90).
In general, molecular imaging has low sensitivity in CNS
sarcoidosis and is not helpful to detect peripheral
nerve disease (53).
Histopathology
Due to the understandable reticence to undertake major
invasive procedures such as biopsy to lesions suspected
of representing central and peripheral nervous system
involvement by sarcoidosis, the histopathologic features
of neurosarcoidosis have been much less thoroughly
evaluated than those of sarcoidosis involving the lungs,
lymph nodes, skin, and other organs. Nonetheless,
pathologic studies on biopsy and excision specimens,
as well as those performed on autopsy material, where
nervous system involvement is found twice as com-
monly as clinically suspected, have shown that neuro-
sarcoidosis is characterized histopathologically by the
same lesions as those found elsewhere in the body, i.e.
the formation of epithelioid granulomas, although these
tend to be located closer to vessels, be smaller, and
contain giant cells less commonly (91). The term
granuloma, derived from the Latin granum (grain),
relates to the typical gross appearance of these lesions,
as tiny (2–4mm) discrete, whitish-grey or yellowish
granules, also called follicles. Neurosarcoidosis is char-
acterized grossly and on imaging studies by either
scattered, barely visible granules (miliary form), or by
larger, grossly visible lesions consisting of a conglomer-
ate of granulomas, which are characteristic of the
nodular form (1–2 cm) and of the tumoral form (over
2 cm) (92) of neurosarcoidosis. The use of high-resolution
cross-sectional imaging has led to an increased recog-
nition of tumoral forms of neurosarcoidosis. Such mass
Figure 2. MRI brain, axial T1 post-contrast images: marked leptomeningeal enhancement at the base of the skull including along the
midbrain (A) (arrow), surrounding the pons/medulla and along cranial nerves VII (B) (arrow). Brainstem enhancement in panel A
represents involvement of pia-arachnoid with extension into Virchow–Robin spaces. Courtesy of Dr Fang Zhu, Chicago.
Figure 3. MRI spinal cord, sagittal T2: spinal meningeal
involvement by sarcoidosis manifesting as linear leptomeningeal
enhancement along the thoracic spinal cord (arrow). Courtesy of
Dr Fang Zhu, Chicago.
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lesions can be mistaken for meningiomas, intraventri-
cular tumors, and cerebellopontine angle tumors.
Nervous system involvement manifests most com-
monly as meningeal involvement, which usually occurs
at the skull base and involves the leptomeninges
(Figure 4), but can extend from the subarachnoid
space into the superficial brain parenchyma along the
Virchow–Robin spaces. The basilar meningeal involve-
ment appears as plaques or pachymeningitis (Figure 5)
and is responsible for multiple cranial nerve and spinal
root palsies. The third ventricle and choroid plexus may
also be invaded by granulomas. All parts of the brain
and spinal cord may be affected, but the most common
sites of brain involvement are the hypothalamus and
pituitary gland (Figure 6), while spinal cord sites prefer-
entially involved are the cervical or thoracic cord.
Peripheral nerve involvement may also occur, as can
muscle involvement, which is very common, but mostly
asymptomatic. In the peripheral nerves, the granuloma-
tous inflammation involves primarily the epineurium and
perineurium and the vasa nervorum (Figure 7).
Microscopically, neurosarcoidosis lesions are charac-
terized by 150–400 mm diameter discrete rounded,
compact collections of epithelioid histiocytes inter-
spersed with lymphocytes and surrounded by a rim
composed of only sparse lymphoid cells (the so-called
‘naked granulomas’), and a variable amount of fibrosis
and collagen deposition, depending on the age of the
granulomas. Granulomas become fibrotic starting from
the periphery toward the center, showing concentric
hyalinizing fibrosis with eventual replacement of the
granulomas by a hyalinized nodular fibrous scar. When
located within the central nervous system parenchyma,
granulomas may be surrounded by dense reactive
gliosis. Within the same lesion, the granulomas of
neurosarcoidosis tend to be of similar size and age,
although sometimes non-fibrotic granulomas may coex-
ist with fibrotic ones. The epithelioid cells are spindle-
shaped, rounded, or polygonal histiocytes with poorly
defined cell borders, moderately abundant pale-staining
cytoplasm, which is usually devoid of phagocytosed
material or pigments, and a single ovoid, bean-shaped
nucleus with fine nuclear chromatin and 1–2 small
nucleoli. The presence of this abundant pale cytoplasm,
imparting them an epithelial-like appearance, is respon-
sible for the designation ‘epithelioid’.
Fusion of the epithelioid cells results in the formation
of multinucleated giant cells. The multinucleated giant
Figure 4. Typical sarcoid granuloma in the subarachnoid space
of the cerebellum (H&E stain, original magnification200):
multinucleated giant cells and clusters of epithelioid histiocytes
surrounded by lymphocytes expand the subarachnoid space.
Underlying cerebellar parenchyma is gliotic.
Figure 5. Neurosarcoidosis involving dura matter, H&E: compact
collection of epithelioid histiocytes and multinucleated giant
cells surrounded by scant lymphocytic infiltrate in densely
fibrotic dura (H&E stain, original magnification400).
Figure 6. Sarcoidosis of pituitary gland, H&E: notice the
multinucleated giant cells and presence of distinct lymphocytic
cuff without significant fibrosis. Pituitary acini are present at the
periphery (H&E stain, original magnification200).
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cells characteristic of epithelioid granulomas, also
referred to as Langhans-type giant cells in honor of
Theodor Langhans (1839–1915), who described them in
1868, usually have 5–20 nuclei located at the periphery
of the cells and arranged in an incomplete semicircle
akin to a horseshoe. Another type of multinucleated
giant cell that may be encountered in epithelioid
granulomas of sarcoidosis, but is not characteristic of
them, is the foreign body giant cell, which is larger, and
has more numerous nuclei, which are randomly dis-
tributed, but usually located in the center of the cell. The
granulomas encountered in neurosarcoidosis are typic-
ally non-necrotizing, or non-caseating. The latter term
refers to the lipid-rich, grossly cheese-like (‘caseous’)
liquefaction necrosis characteristic of tuberculous granu-
lomas. Microscopically, caseous necrosis appears as large
geographic areas of acellular, amorphous, pale eosino-
philic necrosis. This type of necrosis is never seen in
sarcoid granulomas. Small foci of necrosis (granular,
fibrinoid, or eosinophilic) may occasionally be present in
the center of sarcoid granulomas, in a rare form of
neurosarcoidosis referred to as necrotizing neurosarcoi-
dosis. These granulomas with focal areas of coagulative
necrosis are usually found side by side with classic non-
necrotizing granulomas (93). When such necrotic foci are
present, a thorough search for infectious etiologies
should be pursued before concluding that these granu-
lomas are compatible with neurosarcoidosis.
Neurosarcoidosis may also show associated vascular
involvement (vasculitis) with infiltration of the adventitia
and media of small arteries or veins by granulomas, giant
cells, or lymphocytes, which can be responsible for foci
of parenchymal necrosis.
A variety of characteristic but non-specific cytoplasmic
inclusions (asteroid bodies, conchoid bodies, and
Hamazaki–Wesenberg bodies) and crystals (oxalate crys-
tals) can be found in the giant cells of sarcoid granu-
lomas, supportive of the diagnosis of sarcoidosis.
However, none of these inclusions is diagnostic of
sarcoidosis, since they can be found in granulomas of
other etiologies.
Immunohistochemistry
The epithelioid cells and multinucleated giant cells
composing the granulomas stain for histiocytic markers
(CD68, HAM-56, and CD163) and may stain weakly for
CD4. CD4 also stains the T-cells within the granulomas,
which may be more numerous than the epithelioid cells;
the lymphocytes rimming the granulomas are usually T-
cells staining for CD8, possibly admixed with rare CD20-
staining B-cells and CD138-staining plasma cells, as well
as rare tryptase and CD117-staining mast cells. However,
immunostains are rarely needed for diagnostic purposes,
since the granulomas are usually easily identified on
routine (H&E) stained sections, and epithelioid granu-
lomas of various etiologies have similar staining
patterns.
Differential diagnosis
Clinical and imaging findings of neurosarcoidosis are
often indistinguishable from those observed in other
granulomatous disorders affecting the nervous system.
Epithelioid granulomas are not specific for sarcoidosis,
since they represent a non-specific reaction pattern to
various etiologic agents, but can offer some precious
diagnostic clues (94).
Infectious disorders
The most important differential diagnosis is with tuber-
culosis involving the nervous system, especially in areas
where tuberculosis is endemic and in patients who have
lived in such areas or have a history of exposure to
tuberculosis. Nervous system involvement by tubercu-
losis shows a similar radiological and histopathological
distribution with basilar meningeal involvement and
extension into the parenchyma in the form of miliary
granulomas or larger tuberculomas. Although classically
tuberculosis shows large necrotizing granulomas, it may
occasionally show only non-necrotizing granulomas on
biopsy (95), and every effort should be made to rule out
mycobacterial infection by acid-fast stains, auramine
rhodamine stains, immunostains for mycobacteria, as
well as PCR-based molecular diagnostic methods to
demonstrate mycobacteria. It should be kept in mind
that even after using all available methods, including
Figure 7. Non-necrotizing granuloma in the peripheral nerve
(peroneal nerve biopsy): non-necrotizing granuloma is present in
the epineurium (H&E stain, original magnification100).
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cultures, special stains, and PCR-based methods, one
cannot entirely rule out tuberculosis, because the
sensitivities of these methods are rather low and may
vary between institutions. For instance, the reported
sensitivities for acid-fast stains is only 5%–25%, for
culture (which may take 4–8 weeks) only 25%–85%, and
for PCR-based methods around 20%–80% (96). In add-
ition, in patients living in areas endemic for fungal
infections or with a history of travel to such areas,
serologic testing, special stains, and molecular diagnos-
tic methods should be employed to rule out histoplas-
mosis, aspergillosis, and cryptococcosis, all of which may
occasionally only show non-necrotizing granulomas,
especially on small biopsies.
In general, the presence of more than focal necrosis
essentially excludes the diagnosis of sarcoidosis and
strongly suggests an infectious process. Furthermore, all
epithelioid granulomas are composed of epithelioid
histiocytes, associated with variable numbers of lympho-
cytes, plasma cells, neutrophils, eosinophils, and mast
cells. While lymphocytes are always seen in association
with epithelioid granulomas, and may even outnumber
the epithelioid histiocytes in sarcoidosis (97), the pres-
ence of more than occasional plasma cells, neutrophils,
or eosinophils within the center or periphery of granu-
lomas argues against the diagnosis of sarcoidosis and
suggests an infectious etiology. Plasma cells are prom-
inent in the granulomas of syphilis (gumma). When
syphilis is suspected, a correct approach should include
also serologic testing (non-treponemal screening test
such as Venereal Disease Research Laboratory (VDRL),
rapid plasma reagin (RPR), or ICE syphilis recombinant
antigen test) followed by treponemal test to confirm the
disease (e.g. quantitative VDRL/RPR), as they have
demonstrated high sensitivity and specificity (98).
Neutrophils can be seen in suppurative granulomas,
such as those caused by Blastomyces dermatitidis, while
eosinophils characterize parasitic granulomas, where
exposure history, peripheral eosinophilia, and serological
tests for parasite antigens can be also helpful to achieve
the diagnosis (99).
Polarization microscopy should be performed for the
demonstration of potential polarizable foreign sub-
stances, and special stains for acid-fast organisms
(Ziehl–Neelsen, Fite), spirochetes (Warthin–Starry,
Dieterle), fungi (Grocott–Gomori methenamine silver),
and protozoa (Giemsa) have to be performed to rule out
infectious organisms.
Vasculitis
Due to the presence of vasculitis that may be occasion-
ally associated with neurosarcoidosis, the differential
diagnostic considerations also include systemic and
primary central nervous system vasculitides associated
with granuloma formation. Since there may be signifi-
cant histopathologic overlap between these entities and
neurosarcoidosis, clinical and radiological correlation is
mandatory. Granulomatosis with polyangiitis (GPA),
formerly known as Wegener’s granulomatosis, can
involve the central nervous system as an extension
from the nasal cavity, paranasal sinuses, and orbit, and
can affect the optic nerve, chiasma, cranial nerves,
meninges, and the pituitary gland (100).
Histopathologically, this disease is characterized by
granulomatous inflammation and small and medium-
sized vessel vasculitis with associated necrosis in
patients with systemic involvement and ANCA-positive
serology with antibodies to proteinase-3 (PR3) or
myeloperoxidase (MPO). Primary central nervous
system vasculitis (PCNSV) is characterized histologically
by lymphocytic, granulomatous (50%) or necrotizing
(25%) vasculitis of the leptomeningeal and cortical
arteries and veins, which may be associated with
thrombosis of the vessels and parenchymal hemorrhage
or necrosis (101). The differential diagnosis with neuro-
sarcoidosis is difficult, and is based on the presence of
necrotizing vasculitis, vasculitis in the absence of men-
ingeal or parenchymal epithelioid granulomas, and
finally the absence of systemic disease. After exclusion
of infectious etiologies, the exact etiology of the non-
necrotizing granulomatous inflammation cannot be
determined in some patients without systemic mani-
festations of disease. Such ‘pathogen-free granuloma-
tous diseases of the central nervous system’ are
associated with a poor prognosis (102) and may repre-
sent a vasculitis rather than neurosarcoidosis.
Neoplastic disorders
A number of neoplastic conditions are also referred to as
granulomatous and/or may be accompanied by granu-
lomas. These include lymphomatoid granulomatosis
(103), a B-cell lymphoma that may present with exten-
sive infiltration of the meninges, blood vessels, and brain
by at least focally atypical lymphoid cells with plasma-
cytoid features, causing necrosis of the surrounding
tissue, and eosinophilic granuloma, a neoplastic
Langerhans cell proliferation that may involve the skull
and extend to the meninges and the pituitary gland.
Careful histopathologic assessment of the lymphoid and
histiocytic population within and outside the granu-
lomas will disclose the cytologic atypia characteristic of
these conditions and lead to the performance of
confirmatory immunohistochemical stains. Pineal germi-
nomas may be associated with sarcoid-like reactions
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composed of numerous small, non-necrotizing granu-
lomas that may obscure the presence of the neoplastic
germ cells, especially in small biopsies.
Other diseases
Other conditions characterized by non-epithelioid
granulomas may involve the nervous system and can
occasionally enter the differential diagnosis of neurosar-
coidosis. Foreign body giant cell granulomas can occur
as a reaction to various foreign materials, show a
predominance of foreign body type giant cells, fre-
quently found in clusters. The initiating foreign material
may be demonstrated by light microscopy or polariza-
tion microscopy. Palisaded granulomas are characterized
by histiocytes arranged perpendicular at the periphery
of a necrobiotic center and are characteristic of rheuma-
toid nodules, which may occasionally involve the men-
inges. Lipogranulomas or xanthogranulomatous
reactions show abundant foamy histiocytes sometimes
associated with cholesterol clefts and a special type of
multinucleated giant cell, with nuclei circularly arranged
in a peripheral wreath-like arrangement, the Touton-
type giant cells. Such reactions can be encountered as a
reaction to the keratin debris of dermoid or epidermoid
cyst (104) or as part of juvenile xanthogranulomas or
Erdheim–Chester disease.
Diagnostic approach
The traditional 1999 ATS/ERS/WASOG criteria defined
the diagnosis of sarcoidosis with suggestive clinical
picture, histopathological demonstration of non-case-
ating granulomas, and exclusion of other diseases able
to produce similar findings (105). However, these criteria
have not given specific indications for each organ
involvement and can sometimes result in classification
bias or misdiagnosed cases in clinical practice
(27,106,107). In the specific form of neurosarcoidosis,
clinical findings can manifest without systemic or
respiratory symptoms and signs and can be wrongly
attributed to other conditions. Furthermore, the prob-
lem sometimes becomes more complex because other
diseases, such as tumors, vasculitis, or local infections,
occasionally can be found in patients also having
neurosarcoidosis (108).
Several efforts have been made to produce instru-
ments able to establish criteria to assess the probability
of specific organ involvement by sarcoidosis. If another
organ has demonstrated granulomatous inflammation
previously, the WASOG Sarcoidosis Organ Assessment
Instrument predicts clinical manifestations of
neurosarcoidosis as:
 Highly probable: a clinical syndrome consistent with
granulomatous inflammation of the nervous system
plus MRI findings of neurosarcoidosis or CSF exam-
ination suggestive of inflammation
 At least probable: the presence of isolated VII palsy
and negative MRI, clinical syndrome consistent with
granulomatous inflammation of the nervous system,
but MRI or CSF not suggestive for neurosarcoidosis,
 Possible: the occurrence of seizures and/or cognitive
decline with negative MRI
 No consensus: if there was a peripheral neuropathy
involving large fibers or cranial nerve palsies except
for the facial nerve; negative MRI or CSF findings for
neurosarcoidosis or low CSF glucose (109)
This tool has replaced the previous, outdated ACCESS
instrument (108) and enhances the key role of imaging,
in particular MRI, to evaluate rapidly the presence of
nervous system involvement (109). On this basis, a useful
path can indicate an early brain and spinal MRI as a
mandatory step in the diagnosis of neurosarcoidosis
before any invasive approach (Figure 8) (70).
Neurosarcoidosis can be suspected in patients having a
history of systemic sarcoidosis, neurological symptoms,
and suggestive imaging findings. However, neurological
symptoms in patients with systemic disease should not
be attributed to neurosarcoidosis a priori unless histo-
pathologically confirmed (67). This assumption is even
more true in the case of isolated neurosarcoidosis, where
the risk of misdiagnosis is high due to the lack of
findings suggestive of systemic disease, making the
biopsy mandatory.
Treatment
Neurosarcoidosis is a rare condition, therefore treatment
recommendations from randomized clinical trials are
lacking. Whether neurosarcoidosis mandates treatment
or not depends on symptom severity and course of the
disease (111 Q2). In systemic sarcoidosis, common causes of
death are respiratory insufficiency and cardiac involve-
ment; however, long-term immunosuppressive treat-
ments also carry the risk of serious complications (112).
There is general consensus that corticosteroids are the
first-line treatment for neurosarcoidosis (9,26,113,114). If
symptoms are severe, a short course of pulsed intraven-
ous steroid treatment (such as 1 g methylprednisolone/d
for 3–5 days) is usually applied. Thereafter, or if clinical
symptoms are less serious, oral steroids (e.g. 40–80mg
prednisone equivalent/d) should be given for at least
1–3 months, and slowly tapered thereafter to the lowest
effective dose (Figure 9). Patients should be closely
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monitored for side effects of steroid treatment (e.g.
hypertension, diabetes, gastritis). Clinical and neuroima-
ging examinations should be performed at short inter-
vals to determine response to treatment. If a prednisone
maintenance dose of more than 10mg/d is required for
symptom control or if clinical response is insufficient,
adding a steroid-sparing immune-modulating agent is
recommended (26,115). As second-line treatment, there
is clear evidence in favor of the cytostatic methotrexate
(MTX) (10–25mg once a week with folate substitution
5mg/week preferably taken in the morning after MTX
intake). Side effects include neutropenia, as well as liver
and kidney toxicity (8,116–118). Azathioprine with a
slowly increased dose to approximately 2mg/kg b.w.
(200mg/d at the maximum) can be used instead of MTX,
with similar efficacy and steroid-sparing capacity but
more infections as side effects (119). Before starting
azathioprine, activity of the enzyme thiopurinmethyl-
transferase (TPMT) should be determined to detect
patients with a particular sensitivity to myelosuppressive
effects of azathioprine. Leflunomide at 20mg/d may be
similarly effective to MTX with fewer side effects (120).
Based on promising results from neurosarcoidosis
patients treated with mycophenolate mofetil (MMF)
alone or in combination therapy (121–123), we have
increasingly used this substance at a dose of 2 g/d. It is
generally well tolerated and may stabilize the disease
process in steroid-refractory cases (Figure 10).
As third-line therapies, biologicals targeting tumor
necrosis factor-alpha (TNF-alpha) such as infliximab and
adalimumab Q3have been recently used in patients with
neurosarcoidosis (124,125).
Infliximab is applied intravenously at a dose of
3–5mg/kg b.w. with a loading on weeks 0, 2, and 6
and with 4–6-weekly intervals thereafter (126). Since
cases with fast treatment response have been described,
it may even be considered as a fast therapy inducing
agent for patients in whom steroid treatment is contra-
indicated. Before establishing an anti-TNF-alpha therapy,
a latent tuberculosis infection should be ruled out (127).
There are fewer data available about adalimumab;
however, it is likely to be similarly effective in
neurosarcoidosis to infliximab (127). Adalimumab can
be administered either intravenously or subcutaneously
at weekly or bi-weekly intervals. Of note, anti-TNF-alpha
treatment for auto-inflammatory diseases has in rare
cases induced sarcoidosis, so patients should be closely
monitored for this adverse treatment reaction (128).
Figure 8. Suggested diagnostic path for neurosarcoidosis. From
Wegener, S. et al. Clinically isolated neurosarcoidosis: a recom-
mended diagnostic path. Eur Neurol. 2015;73:71–7, with
permission from S. Karger AG, Basel. CINS¼ clinically isolated
neurosarcoidosis.
Figure 9. Neurosarcoidosis treatment response to prednisone. A:
MRI of a 57-year-old patient with probable neurosarcoidosis. The
singular FLAIR hyperintense, contrast-enhancing CNS lesion on
T1-weighted images (arrows) is completely remittent after oral
prednisone therapy (B). Courtesy of Dr S. Sartoretti, Winterthur.
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There is a single case report about successful treatment
of neurosarcoidosis with the monoclonal anti-CD20
antibody rituximab (129). We consider this b-cell
Q4 depleting, costly agent a third-line therapy in neurosar-
coidosis. Due to the potential toxicity and the treatment
alternatives discussed above, we recommend using
cytostatic treatment with cyclophosphamide and cyclo-
sporine only in therapy-refractive cases based on indi-
vidual risk/benefit decisions (26,45,130). When clinical
deterioration progresses despite intensive immune-
modulating treatment in neurosarcoidosis, a progressive
multifocal leukoencephalopathy should be considered.
This potentially fatal treatment complication in immuno-
compromised patients can be easily missed (131).
With head-to-head comparisons of medical treatment
for neurosarcoidosis still lacking due to the rarity of the
disease and an increasing number of immunomodulat-
ing therapies at hand, novel therapeutic approaches are
to be expected within the next years.
Conclusion
Neurosarcoidosis remains a diagnostic and therapeutic
challenge. The recognition of this uncommon disorder
depends first on non-specific clinical and radiological
findings, that can be found almost always in several
other (immunological and not) neurological conditions,
and then on the lack of comparative trials aimed at
assessing the efficacy of the drug treatment in affected
patients. Clinical algorithms could be helpful to assess
nervous system involvement, but should be integrated
with biopsy of affected tissues, because only histopath-
ology can reveal the presence of non-caseating granu-
lomas in the nervous system, the histological hallmark of
neurosarcoidosis.
In view of the high genetic predisposition of some
patients to manifest certain clinical pictures of neuro-
sarcoidosis, more studies should investigate the genetic
signature in these patients. The near future could see an
early diagnosis of certain forms of neurosarcoidosis
based on the study of patients’ genetic profile, in
particular of those having risk factors for neurosarcoi-
dosis such as long-standing sarcoidosis and symptoms
as cognitive dysfunction and fatigue. At present, a
thorough multidisciplinary evaluation involving clin-
icians, radiologists, and pathologists is essential to
achieve a correct and early diagnosis. Although there
are no specific recommendations, corticosteroids should
Figure 10.Q6 Spinal cord neurosarcoidosis treatment response to prednisone and mycophenolate mofetil. T2-weighted (left) and T1-
weighted post-contrast images (right) of the cervical spinal cord in a 51-year-old patient with neurosarcoidosis and a tetraparesis
below cervical C3 level. A: Before treatment. Arrows point to T2 hyperintensity and T1 contrast enhancement in cervical spinal cord,
spreading over multiple cervical segments. B: Dramatic improvement after pulsed steroid treatment slowly tapered off. C: Relapse with
clinical and imaging correlate (arrows) 2 months after complete discontinuation of prednisone. D: Clinical and imaging findings are
improved under mycophenolate mofetil 3 g/d + 5 mg prednisone (no T1 post-contrast image available at that time point). Courtesy of
Dr A. Rosskopf, Balgrist.
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be used as first-line treatment for neurosarcoidosis,
followed by immunosuppressive therapy in non-respon-
sive patients.
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